Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Isabelle Freiling, PhD, Nicole M. Krause, MA, and Dietram A. Scheufele, PhD
Misinformation is an urgent new problem, so health professions communities need solutions as much as they need to be wary of ethical pitfalls of rushed interventions.
AMA J Ethics. 2023;25(3):E228-237. doi:
10.1001/amajethics.2023.228.